GKO Stock Overview
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GlycoMimetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.71 |
| 52 Week High | US$3.19 |
| 52 Week Low | US$1.04 |
| Beta | 2.19 |
| 1 Month Change | -33.36% |
| 3 Month Change | -40.66% |
| 1 Year Change | 39.38% |
| 3 Year Change | -19.53% |
| 5 Year Change | -83.52% |
| Change since IPO | -75.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| GKO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -19.7% | -0.2% | 0.5% |
| 1Y | 39.4% | -22.8% | 1.3% |
Price Volatility
| GKO volatility | |
|---|---|
| GKO Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GKO's share price has been volatile over the past 3 months.
Volatility Over Time: GKO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 35 | Harout Semerjian | www.glycomimetics.com |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.
GlycoMimetics, Inc. Fundamentals Summary
| GKO fundamental statistics | |
|---|---|
| Market cap | €111.45m |
| Earnings (TTM) | -€34.40m |
| Revenue (TTM) | €9.32k |
Over9,999x
P/S Ratio-3.2x
P/E RatioIs GKO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GKO income statement (TTM) | |
|---|---|
| Revenue | US$10.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00k |
| Other Expenses | US$36.91m |
| Earnings | -US$36.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 100.00% |
| Net Profit Margin | -368,994.20% |
| Debt/Equity Ratio | 0% |
How did GKO perform over the long term?
See historical performance and comparison